A drug's aqueous solubility is defined as the ability to dissolve in a particular solvent, and it
is currently a major hurdle in bringing new drug molecules to the market. According to some …

Over the past 3 years, the first bivalent protein degraders intentionally designed for targeted
protein degradation (TPD) have advanced to clinical trials, with an initial focus on …

Selecting the appropriate formulation and solubility-enabling technology for poorly water
soluble drugs is an essential element in the development of formulations for paediatric …

Hydrogel-forming microarray patches (HF-MAPs) are used to circumvent the skin barrier and
facilitate the noninvasive transdermal delivery of many hydrophilic substances. However …

Cancer has recently surpassed heart disease as the leading cause of deaths worldwide for
the age group 45–65 and has been the primary focus for biomedical researchers. Presently …

Protein hydrolysis is a process used in the food industry to generate bioactive peptides of
low molecular weight and with additional health benefits, such as antihypertensive …

Solid dispersions have achieved significant interest as an effective means of enhancing the
dissolution rate and thus the bioavailability of a range of weakly water‐soluble drugs. Solid …

Poorly water-soluble drugs pose a significant challenge to developability due to poor oral
absorption leading to poor bioavailability. Several approaches exist that improve the oral …

Abstract We, the Editors and Publisher of Drug Delivery have retracted the following article:
Sultan Alshehri, Syed Sarim Imam, Afzal Hussain, Mohammad A. Altamimi, Nabil K …

Poorly soluble drugs constitute more than 60% of currently marketed pharmaceuticals with
over two‐thirds of promising new chemical entities failing to enter a clinical setting due to …